Two strategic projects from IBG receive TÜSEB support
Two strategic projects from IBG receive TÜSEB support
The projects selected for funding under the 2025-B-01 Group B R&D Project Call—launched by the Health Institutes of Türkiye (TÜSEB) to support strategic R&D projects in health sciences and technologies—have been announced. Following a rigorous evaluation process, two projects led by researchers from the Izmir Biomedicine and Genome Center (IBG) were selected for support.
The project titled “Development, In Silico Optimization, Production, and In Vivo/In Vitro Characterization of Therapeutic Anti-PD-1 Nanocores”, led by Dr.Sibel Kalyoncu Uzunlar from İBG, aims to develop innovative immunotherapeutic solutions. The project focuses on the development of next-generation antibody drugs that could be effective in treating various diseases, particularly cancer. Prof. Dr. Mehmet İnan, Dr. Gerhard Wingender, and Dr. Ezgi Karaca Erek, researchers from İBG, are also part of the project team.
Another project selected for funding is titled “Development of a Tear Drop Based on Organoid Secretome”, led by Assoc. Prof. Sinan Güven. This project aims to develop a biotechnological product for the treatment of dry eye and related ophthalmological conditions. The biologically based eye drop, to be produced using organoid technology, is intended to offer an innovative alternative to existing treatments. The project team includes Prof. Dr. Canan Aslı Yıldırım (Department of Ophthalmology, DEU), Prof. Dr. Emirhan Nemutlu, and Assoc. Prof. Selin Seda Timur (Faculty of Pharmacy, Hacettepe Uni.).
These achievements reinforce IBG’s vision of advancing Turkey’s R&D capacity in the field of health.